MedTrace Logo

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

NCT01928628 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 449

Last updated 2013-08-28

No results posted yet for this study

Summary

This study aims to compare and assess the efficacy and the safety of the combination agent of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential hypertension

Conditions

Interventions

DRUG

Lercanidipine 10mg

DRUG

Lercanidipine10mg /Valsartan 80mg

DRUG

Lercanidipine 10mg /Valsartan 160mg

DRUG

Lercanidipin 10mg Placebo

DRUG

Lercanidipine10mg /Valsartan 80mg Placebo

DRUG

Lercanidipine 10mg /Valsartan 160mg Placebo

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928628 on ClinicalTrials.gov